Mike Dudley, PharmD
@mndudley.bsky.social
President, CEO, and co-Founder of Qpex Biopharma, developing new antibiotics in San Diego.
Rust never sleeps.
Rust never sleeps.
Memo to US medical professional organizations: @ezrakleinbot.bsky.social is right. Avoid impulse to react to everything. Pick topics and respond carefully. Don’t exhaust yourselves. #IDSky www.nytimes.com/2025/02/02/o...
Opinion | Don’t Believe Him
Look closely at the first two weeks of Donald Trump’s second term and you’ll see something very different than what he wants you to see.
www.nytimes.com
February 2, 2025 at 9:11 PM
Memo to US medical professional organizations: @ezrakleinbot.bsky.social is right. Avoid impulse to react to everything. Pick topics and respond carefully. Don’t exhaust yourselves. #IDSky www.nytimes.com/2025/02/02/o...
Important new tools that are critical for assessing societal value of new medicines.This analysis has been missing for new & old antimicrobials for #AMR. Tired old approaches have had a limited impact on reforming payment mechanisms to sustain innovation. Lots here. www.degruyter.com/document/doi...
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value asse...
www.degruyter.com
November 17, 2024 at 2:43 PM
Important new tools that are critical for assessing societal value of new medicines.This analysis has been missing for new & old antimicrobials for #AMR. Tired old approaches have had a limited impact on reforming payment mechanisms to sustain innovation. Lots here. www.degruyter.com/document/doi...
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value asse...
www.degruyter.com
November 16, 2024 at 8:20 PM
Important new tools that are critical for assessing societal value of new medicines.This analysis has been missing for new & old antimicrobials for #AMR. Tired old approaches have had a limited impact on reforming payment mechanisms to sustain innovation. Lots here. www.degruyter.com/document/doi...